All
Initial PARP Inhibitor Use for Ovarian Cancer May Not Lead to Resistance in Secondary Use
March 18th 2019Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.
Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy
March 18th 2019Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.
Zejula Maintenance Therapy Extends Symptom-Free Survival in Recurrent Ovarian Cancer
March 17th 2019Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.
Genomics Data Could Lead to New Treatments for Children
March 12th 2019St. Jude Children’s Research Hospital is offering cloud-based access to the fully sequenced genomes of 10,000 pediatric patients with cancer, in the hopes that sharing the information will lead to the highest possible number of treatment breakthroughs.
The Devil We Know: Secondhand Smoke and Cancer Fears
March 12th 2019As a breast cancer survivor, I have become more active in my efforts to call attention to problems with secondhand smoke in my community. Since I know that exposure is not healthy, lobbying for changes in attitudes, as well as policies, makes me feel more empowered.
The FDA Approves Fourth Herceptin Biosimilar
March 12th 2019The Food and Drug Administration (FDA) has granted an approval to Trazimera (PF-05280014; trastuzumab-qyyp), a Herceptin (trastuzumab) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer
March 11th 2019The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.